GLP-1 Medications Articles - Page 72

China Biotech Targets 2028 Trials for Semaglutide Nasal Spray Like Wegovy

A Shanghai-based biotech is developing a nasal spray version of semaglutide, the key ingredient in Novo Nordisk's Wegovy, with global clinical trials targeted for completion by 2028. This experimental weight-management spray promises lower costs than tablets and better suitability for long-term use. As Novo's patent nears expiration in China, competition heats up in the booming GLP-1 market.

Shotlee·Feb 10, 2026·4 min read

GLP-1 Medications

Oral GLP-1s Benefit HF Patients: SOUL Trial Subanalysis

A subanalysis of the SOUL trial reveals that once-daily oral semaglutide (Rybelsus) lowers the risk of heart failure hospitalization, urgent visits, or CV death by 22% in patients with HF, diabetes, and ASCVD or CKD. Those with preserved ejection fraction (HFpEF) saw even greater protection at 41%. Experts highlight this as a key option for frail patients avoiding injections.

Shotlee·Feb 9, 2026·6 min read

GLP-1 Medications

Oral Semaglutide Reduces Heart Failure Risk in Type 2 Diabetes: SOUL Trial

New analysis from the SOUL trial reveals oral semaglutide significantly reduces heart failure risks in type 2 diabetes patients who already have the condition. This benefit is especially notable in HFpEF cases, without compromising safety. Discover the details and implications for managing cardiometabolic disease.

Shotlee·Feb 8, 2026·5 min read

Events & Nutrition

GLP-1 Era Nutrition Symposium on Cardiac Recovery Held in Dhaka

A pivotal symposium on 'Nutrition in Clinical Practice: From GLP-1 Era to Cardiac Recovery' drew 150 nutrition professionals to Dhaka's KIB Convention Hall. Chaired by renowned dietician Akhtarun Nahar Alo, the event featured keynote speakers from NICVD and BIRDEM, followed by the launch of Nutricaa Limited's OPTIMA meal replacement. This gathering highlights the growing intersection of GLP-1 therapies and targeted nutrition for cardiac recovery.

Shotlee·Feb 8, 2026·5 min read

GLP-1 Medications

Hims & Hers Shares Sink 16% as FDA Halts Wegovy Copycat Pill

Hims & Hers Health Inc. (HIMS) has halted sales of its copycat Wegovy weight loss pill just two days after launch, leading to a 16% plunge in shares amid FDA warnings and Novo Nordisk threats. This marks a regulatory pivot as GLP-1 shortages ease. Patients and investors should note the growing scrutiny on compounded versions of popular drugs like Wegovy.

Shotlee·Feb 8, 2026·5 min read

GLP-1 Medications

Hims Stops Compounded Wegovy Pill After FDA Scrutiny

Telehealth giant Hims & Hers has abruptly stopped offering its newly launched compounded version of Novo Nordisk's Wegovy pill amid FDA scrutiny. The decision follows constructive industry conversations, raising questions about compounded GLP-1 availability. Patients seeking semaglutide for weight management now face shifting options.

Shotlee·Feb 8, 2026·5 min read

GLP-1 Medications

Taiwan FDA Warns: GLP-1 Weight Loss Drugs Like Ozempic Linked to 21 Adverse R...

Taiwan's Food and Drug Administration (FDA) has reported 21 cases of suspected adverse reactions to GLP-1 receptor agonists like Ozempic used for weight loss. Symptoms include gastrointestinal disorders, hypoglycemia, nausea, and more. Amid global concerns from US lawsuits and UK pancreatitis warnings, the FDA urges doctor-prescribed use only.

Shotlee·Feb 7, 2026·5 min read

GLP-1 Medications

Experts Warn Against 'Worrying' Rise in Dangerous Weight-Loss Jab Hacks

Experts are sounding the alarm on a 'worrying' surge in dangerous weight-loss 'jab hacks' like microdosing Wegovy or sourcing from beauty therapists. A survey shows 32% of UK users microdose and 28% buy unlicensed drugs amid rising costs. Discover the real risks and expert advice for safe use.

Shotlee·Feb 7, 2026·6 min read

GLP-1 Medications

Weight-Loss Price Wars Upend Big Pharma's Model

Two years ago, GLP-1 prescriptions cost over $1,000 monthly for uninsured patients. Now, Wegovy's pill starts at $149, flipping Big Pharma's playbook amid fierce price wars. As Novo Nordisk forecasts sales drops and Eli Lilly surges, discover how consumer demand is reshaping obesity treatments.

Shotlee·Feb 7, 2026·6 min read

GLP-1 Medications

Latest Articles

China Biotech Targets 2028 Trials for Semaglutide Nasal Spray Like Wegovy

Oral GLP-1s Benefit HF Patients: SOUL Trial Subanalysis

Oral Semaglutide Reduces Heart Failure Risk in Type 2 Diabetes: SOUL Trial

GLP-1 Era Nutrition Symposium on Cardiac Recovery Held in Dhaka

Hims & Hers Shares Sink 16% as FDA Halts Wegovy Copycat Pill

Hims Stops Compounded Wegovy Pill After FDA Scrutiny

Taiwan FDA Warns: GLP-1 Weight Loss Drugs Like Ozempic Linked to 21 Adverse R...

Experts Warn Against 'Worrying' Rise in Dangerous Weight-Loss Jab Hacks

Weight-Loss Price Wars Upend Big Pharma's Model

People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less

Ozempic, Mounjaro & More: Yale Study Exposes Risky Online GLP-1 Prescribing

Beyond Healthspan: The New Midlife Goal for Men

GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia

Ozempic and Similar Weight-Loss Medications Linked to 30% Lower Breast Cancer Risk